Abstract: A modular reaction vessel cartridge for a photometric reagent analyzer includes a hollow cuvette defining a filling chamber defining an upper orifice through which a first reagent is communicated, a dispensing opening below the upper orifice and through which a second reagent is communicated into the filling chamber, a read chamber below the dispensing opening and fluidically communicating with the filling chamber, and a dispensing control chamber above the read chamber having an exit fluidically communicating with the dispensing opening, defining a receiving opening through which the second reagent is communicated into the control chamber, and a plunger slidably and fluid-tightly disposed in the control chamber and defining therebetween a volume shaped to hold the second reagent such that, responsive to the plunger being moved into the filling chamber, fluid in the control chamber is dispensed into at least the filling chamber without fluid in the cuvette being transferred out from the cuvette.

Abstract: Provided are methods of making preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms and therapeutic methods using them. The preparations are suitable for treatment of allograft or xenograft rejection, diseases involving inflammation or inappropriate complement activation, and thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid: mannose molar ratio of .gtoreq.0.25.

Abstract: Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid:mannose molar ratio of .gtoreq.0.25.

Abstract: Soluble polypeptides are provided that comprise no more than three short consensus repeats (SCR) of Complement Receptor 1, and contain SCR3. DNA molecules encoding such soluble polypeptides, as well as methods, vectors and host cells, also are provided.

Abstract: A soluble polypeptide comprising, in sequence, one to four short consensus repeats (SCR) selected from SCR 1, 2, 3 and 4 of long homologous repeat A (LHR-A) as the only structurally and functionally intact SCR domains of CR1 and including at least SCR3.